BIOCRYST PHARMACEUTICALS INC (BCRX) Q3 2025 10-Q Quarterly Report
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR BIOCRYST PHARMACEUTICALS INC (BCRX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
BIOCRYST PHARMACEUTICALS INC Q3 2025 10-Q Analysis
Risk Factors
- • No new risk factors identified this quarter; risk disclosures unchanged from most recent 10-K
- • Updated financial risk: uncertainty in sustaining profitability due to reliance on commercialization, competition, and achieving regulatory approvals
BIOCRYST PHARMACEUTICALS INC Q3 2025 Quarterly FinancialsXBRL
Revenue
$159M
▲ +36.1% YoY▼ -2.4% QoQ
Net Income
$13M
▲ +191.9% YoY▲ +153.7% QoQ
Operating Margin
18.6%
▲ +1199bp YoY▲ +33bp QoQ
Net Margin
8.1%
▲ +2008bp YoY▲ +498bp QoQ
ROE
-3.3%
Total Assets
$446M
EPS (Diluted)
$0.06
▲ +185.7% YoY▲ +200.0% QoQ
Operating Cash Flow
$42M
▲ +404.8% YoY▲ +0.8% QoQ
Source: XBRL data from BIOCRYST PHARMACEUTICALS INC Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on BIOCRYST PHARMACEUTICALS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.